|

Intismeran autogene Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: V940, mRNA-4157

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • Merck Sharp & Dohme LLC3

Indications

  • Cancer3
  • Lung Cancer2
  • Carcinoma in Situ1
  • Non-Muscle Invasive Bladder Neoplasms1
  • Urinary Bladder Neoplasms1

Anchorage, Alaska1 trial

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Alaska Oncology and Hematology ( Site 0039)

Phase 3

Gilbert, Arizona1 trial

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Banner MD Anderson Cancer Center ( Site 0181)

Phase 3

Bakersfield, California1 trial

A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)

Michael G Oefelein Clinical Trials ( Site 0138)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.